Nasdaq · CIK 0001585608
JAGX Jaguar Health, Inc.
Insider trading from SEC Form 4. Last filing Mar 12, 2026.
Jaguar Health, Inc. (JAGX) has 26 SEC Form 4 filings on file from 9 insiders, the latest filed on Mar 12, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Signals
Open-market buys and sells at Jaguar Health, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The newest 50 of 59 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | John Micek director | AGrant or award Common Stock | +7,377 | $0.00 | $0 | 7,430 | Mar 12, 2026 |
| Dec 11, 2025 | John Micek director | AGrant or award Stock Option (right to buy)derivative | +7,377 | $0.00 | $0 | 7,377 | Mar 12, 2026 |
| Dec 11, 2025 | Steven R. King See Remarks | AGrant or award Common Stock | +11,740 | $0.00 | $0 | 11,885 | Jan 21, 2026 |
| Dec 11, 2025 | Jonathan S. Wolin See Remarks | AGrant or award Common Stock | +11,740 | $0.00 | $0 | 11,938 | Jan 21, 2026 |
| Dec 11, 2025 | Lisa A Conte See Remarks | AGrant or award Common Stock | +28,592 | $0.00 | $0 | 29,258 | Jan 21, 2026 |
| Dec 11, 2025 | Jonathan S. Wolin See Remarks | AGrant or award Stock Option (right to buy)derivative | +11,740 | $0.00 | $0 | 11,740 | Jan 21, 2026 |
| Dec 11, 2025 | Lisa A Conte See Remarks | AGrant or award Stock Option (right to buy)derivative | +28,592 | $0.00 | $0 | 28,592 | Jan 21, 2026 |
| Dec 11, 2025 | Steven R. King See Remarks | AGrant or award Stock Option (right to buy)derivative | +11,740 | $0.00 | $0 | 11,740 | Jan 21, 2026 |
| Dec 11, 2025 | Jonathan B. Siegel director | AGrant or award Common Stock | +7,377 | $0.00 | $0 | 7,423 | Dec 15, 2025 |
| Dec 11, 2025 | Carol R. Lizak Chief Financial Officer | AGrant or award Common Stock | +11,740 | $0.00 | $0 | 11,911 | Dec 15, 2025 |
| Dec 11, 2025 | Pravin R Chaturvedi Chief Scientific Officer | AGrant or award Common Stock | +11,740 | $0.00 | $0 | 11,938 | Dec 15, 2025 |
| Dec 11, 2025 | James J Bochnowski director | AGrant or award Common Stock | +6,363 | $0.00 | $0 | 6,415 | Dec 15, 2025 |
| Dec 11, 2025 | Anula Jayasuriya director | AGrant or award Common Stock | +5,870 | $0.00 | $0 | 5,916 | Dec 15, 2025 |
| Dec 11, 2025 | Anula Jayasuriya director | AGrant or award Stock Option (right to buy)derivative | +5,870 | $0.00 | $0 | 5,870 | Dec 15, 2025 |
| Dec 11, 2025 | Pravin R Chaturvedi Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +11,740 | $0.00 | $0 | 11,740 | Dec 15, 2025 |
| Dec 11, 2025 | Carol R. Lizak Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +11,740 | $0.00 | $0 | 11,740 | Dec 15, 2025 |
| Dec 11, 2025 | Jonathan B. Siegel director | AGrant or award Stock Option (right to buy)derivative | +7,377 | $0.00 | $0 | 7,377 | Dec 15, 2025 |
| Dec 11, 2025 | James J Bochnowski director | AGrant or award Stock Option (right to buy)derivative | +6,363 | $0.00 | $0 | 6,363 | Dec 15, 2025 |
| Jun 24, 2025 | John Micek director | DDisposition to issuer Convertible Promissory Notederivative | -9,000 | $50,000.00 | $450M | 0 | Jun 26, 2025 |
| Jun 24, 2025 | Jonathan B. Siegel director | DDisposition to issuer Convertible Promissory Notederivativeindirect: See footnote | -9,000 | $50,000.00 | $450M | 0 | Jun 26, 2025 |
| Jun 24, 2025 | Lisa A Conte CEO and President | DDisposition to issuer Convertible Promissory Notederivative | -9,000 | $50,000.00 | $450M | 0 | Jun 26, 2025 |
| Jun 24, 2025 | Pravin R Chaturvedi Chief Scientific Officer | DDisposition to issuer Convertible Promissory Notederivative | -3,600 | $20,000.00 | $72M | 0 | Jun 26, 2025 |
| Jun 24, 2025 | James J Bochnowski director | DDisposition to issuer Convertible Promissory Notederivativeindirect: See footnote | -27,002 | $150,000.00 | $4.1B | 0 | Jun 26, 2025 |
| Jun 24, 2025 | Jonathan S. Wolin See Remarks | DDisposition to issuer Convertible Promissory Notederivative | -9,000 | $50,000.00 | $450M | 0 | Jun 26, 2025 |
| Jun 24, 2025 | Steven R. King See Remarks | DDisposition to issuer Convertible Promissory Notederivative | -3,600 | $20,000.00 | $72M | 0 | Jun 26, 2025 |
| Jun 24, 2025 | Steven R. King See Remarks | AGrant or award Convertible Promissory Notederivative | +3,785 | $20.00 | $76k | 3,785 | Jun 26, 2025 |
| Jun 24, 2025 | John Micek director | AGrant or award Convertible Promissory Notederivative | +9,462 | $50,000.00 | $473M | 9,462 | Jun 26, 2025 |
| Jun 24, 2025 | Jonathan B. Siegel director | AGrant or award Convertible Promissory Notederivativeindirect: See footnote | +9,462 | $50,000.00 | $473M | 9,462 | Jun 26, 2025 |
| Jun 24, 2025 | James J Bochnowski director | AGrant or award Convertible Promissory Notederivativeindirect: See footnote | +28,388 | $150,000.00 | $4.3B | 28,388 | Jun 26, 2025 |
| Jun 24, 2025 | Lisa A Conte CEO and President | AGrant or award Convertible Promissory Notederivative | +9,462 | $50,000.00 | $473M | 9,462 | Jun 26, 2025 |
| Jun 24, 2025 | Pravin R Chaturvedi Chief Scientific Officer | AGrant or award Convertible Promissory Notederivative | +3,785 | $20,000.00 | $76M | 3,785 | Jun 26, 2025 |
| Jun 24, 2025 | Jonathan S. Wolin See Remarks | AGrant or award Convertible Promissory Notederivative | +9,462 | $50,000.00 | $473M | 9,462 | Jun 26, 2025 |
| Jun 24, 2025 | Steven R. King See Remarks | AGrant or award Warrant to Purchase Common Stockderivative | +7,304 | - | - | 3,600 | Jun 26, 2025 |
| Jun 24, 2025 | John Micek director | AGrant or award Warrant to Purchase Common Stockderivative | +18,262 | - | - | 9,000 | Jun 26, 2025 |
| Jun 24, 2025 | Jonathan B. Siegel director | AGrant or award Warrant to Purchase Common Stockderivativeindirect: See footnote | +18,262 | - | - | 9,000 | Jun 26, 2025 |
| Jun 24, 2025 | James J Bochnowski director | AGrant or award Warrant to Purchase Common Stockderivativeindirect: See footnote | +54,786 | - | - | 27,002 | Jun 26, 2025 |
| Jun 24, 2025 | Lisa A Conte CEO and President | AGrant or award Warrant to Purchase Common Stockderivative | +18,262 | - | - | 9,000 | Jun 26, 2025 |
| Jun 24, 2025 | Pravin R Chaturvedi Chief Scientific Officer | AGrant or award Warrant to Purchase Common Stockderivative | +7,304 | - | - | 3,600 | Jun 26, 2025 |
| Jun 24, 2025 | Jonathan S. Wolin See Remarks | AGrant or award Warrant to Purchase Common Stockderivative | +18,262 | - | - | 9,000 | Jun 26, 2025 |
| May 17, 2025 | Lisa A Conte CEO and President | MOption exercise Common Stock | +2 | - | - | 666 | May 20, 2025 |
| May 17, 2025 | Steven R. King See Remarks | MOption exercise Common Stock | +1 | - | - | 145 | May 20, 2025 |
| May 17, 2025 | Lisa A Conte CEO and President | MOption exercise Restricted stock unitsderivative | -2 | $0.00 | $0 | 0 | May 20, 2025 |
| May 17, 2025 | Steven R. King See Remarks | MOption exercise Restricted stock unitsderivative | -1 | $0.00 | $0 | 0 | May 20, 2025 |
| Mar 31, 2025 | James J Bochnowski director | POpen-market purchase Convertible Promissory Notederivativeindirect: See Footnote | +27,002 | $150,000.00 | $4.1B | 27,002 | Apr 2, 2025 |
| Mar 31, 2025 | Lisa A Conte CEO and President | POpen-market purchase Convertible Promissory Notederivative | +9,000 | $50,000.00 | $450M | 9,000 | Apr 2, 2025 |
| Mar 31, 2025 | Steven R. King See Remarks | POpen-market purchase Convertible Promissory Notederivative | +3,600 | $20,000.00 | $72M | 3,600 | Apr 2, 2025 |
| Mar 31, 2025 | Jonathan B. Siegel director | POpen-market purchase Convertible Promissory Notederivativeindirect: See Footnote | +9,000 | $50,000.00 | $450M | 9,000 | Apr 2, 2025 |
| Mar 31, 2025 | Jonathan S. Wolin See Remarks | POpen-market purchase Convertible Promissory Notederivative | +9,000 | $50,000.00 | $450M | 9,000 | Apr 2, 2025 |
| Mar 31, 2025 | Pravin R Chaturvedi Chief Scientific Officer | POpen-market purchase Convertible Promissory Notederivative | +3,600 | $20,000.00 | $72M | 3,600 | Apr 2, 2025 |
| Mar 31, 2025 | Carol R. Lizak Chief Financial Officer | POpen-market purchase Convertible Promissory Notederivative | +5,400 | $30,000.00 | $162M | 5,400 | Apr 2, 2025 |
50 of 59 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- James J Bochnowskidirector
- Lisa A ConteSee Remarks
- Pravin R ChaturvediChief Scientific Officer
- Anula Jayasuriyadirector
- Steven R. KingSee Remarks
- Carol R. LizakChief Financial Officer
- John Micekdirector
- Jonathan B. Siegeldirector
- Jonathan S. WolinSee Remarks
Questions about JAGX
Answered from the filings on this page, as of the latest one.
Are insiders buying JAGX?
No. In the last 90 days no insider at Jaguar Health, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade JAGX on the open market?
No open-market trade has been scored at Jaguar Health, Inc.. The latest Form 4 on file was filed on Mar 12, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Jaguar Health, Inc.?
9 people have filed a Form 4 at Jaguar Health, Inc., among them James J Bochnowski (director), Lisa A Conte (See Remarks), Pravin R Chaturvedi (Chief Scientific Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.